BACKGROUND: Given that continued smoking after a cancer diagnosis increases the risk of adverse health outcomes, patients with cancer are strongly advised to quit. Despite a current lack of evidence regarding their safety and effectiveness as a cessation tool, electronic cigarettes (E-cigarettes) are becoming increasingly popular. To guide oncologists' communication with their patients about E-cigarette use, this article provides what to the authors' knowledge is the first published clinical data regarding E-cigarette use and cessation outcomes among patients with cancer. METHODS: A total of 1074 participants included smokers (patients with cancer) who recently enrolled in a tobacco treatment program at a comprehensive cancer center. Standard demographic, tobacco use history, and follow-up cessation outcomes were assessed. RESULTS: A 3-fold increase in E-cigarette use was observed from 2012 to 2013 (10.6% vs 38.5%). E-cigarette users were more nicotine dependent than nonusers, had more prior quit attempts, and were more likely to be diagnosed with thoracic and head or neck cancers. Using a complete case analysis, E-cigarette users were as likely to be smoking at the time of follow-up as nonusers (odds ratio, 1.0; 95% confidence interval, 0.5-1.7). Using an intention-to-treat analysis, E-cigarette users were twice as likely to be smoking at the time of follow-up as nonusers (odds ratio, 2.0; 95% confidence interval, 1.2-3.3). CONCLUSIONS: The high rate of E-cigarette use observed is consistent with recent articles highlighting increased E-cigarette use in the general population. The current longitudinal findings raise doubts concerning the usefulness of E-cigarettes for facilitating smoking cessation among patients with cancer. Further research is needed to evaluate the safety and efficacy of E-cigarettes as a cessation treatment for patients with cancer.
BACKGROUND: Given that continued smoking after a cancer diagnosis increases the risk of adverse health outcomes, patients with cancer are strongly advised to quit. Despite a current lack of evidence regarding their safety and effectiveness as a cessation tool, electronic cigarettes (E-cigarettes) are becoming increasingly popular. To guide oncologists' communication with their patients about E-cigarette use, this article provides what to the authors' knowledge is the first published clinical data regarding E-cigarette use and cessation outcomes among patients with cancer. METHODS: A total of 1074 participants included smokers (patients with cancer) who recently enrolled in a tobacco treatment program at a comprehensive cancer center. Standard demographic, tobacco use history, and follow-up cessation outcomes were assessed. RESULTS: A 3-fold increase in E-cigarette use was observed from 2012 to 2013 (10.6% vs 38.5%). E-cigarette users were more nicotine dependent than nonusers, had more prior quit attempts, and were more likely to be diagnosed with thoracic and head or neck cancers. Using a complete case analysis, E-cigarette users were as likely to be smoking at the time of follow-up as nonusers (odds ratio, 1.0; 95% confidence interval, 0.5-1.7). Using an intention-to-treat analysis, E-cigarette users were twice as likely to be smoking at the time of follow-up as nonusers (odds ratio, 2.0; 95% confidence interval, 1.2-3.3). CONCLUSIONS: The high rate of E-cigarette use observed is consistent with recent articles highlighting increased E-cigarette use in the general population. The current longitudinal findings raise doubts concerning the usefulness of E-cigarettes for facilitating smoking cessation among patients with cancer. Further research is needed to evaluate the safety and efficacy of E-cigarettes as a cessation treatment for patients with cancer.
Authors: Csaba Gajdos; Mary T Hawn; Elizabeth J Campagna; William G Henderson; Jasvinder A Singh; Thomas Houston Journal: Ann Surg Oncol Date: 2011-11-08 Impact factor: 5.344
Authors: Sarah E Adkison; Richard J O'Connor; Maansi Bansal-Travers; Andrew Hyland; Ron Borland; Hua-Hie Yong; K Michael Cummings; Ann McNeill; James F Thrasher; David Hammond; Geoffrey T Fong Journal: Am J Prev Med Date: 2013-03 Impact factor: 5.043
Authors: Adam O Goldstein; Carol E Ripley-Moffitt; Donald E Pathman; Katharine M Patsakham Journal: Nicotine Tob Res Date: 2012-04-11 Impact factor: 4.244
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Maciej Lukasz Goniewicz; Jakub Knysak; Michal Gawron; Leon Kosmider; Andrzej Sobczak; Jolanta Kurek; Adam Prokopowicz; Magdalena Jablonska-Czapla; Czeslawa Rosik-Dulewska; Christopher Havel; Peyton Jacob; Neal Benowitz Journal: Tob Control Date: 2013-03-06 Impact factor: 7.552
Authors: Sara Kalkhoran; Nicholas Alvarado; Maya Vijayaraghavan; Paula J Lum; Patrick Yuan; Jason M Satterfield Journal: J Gen Intern Med Date: 2017-07-14 Impact factor: 5.128
Authors: Tarik Benmarhnia; John P Pierce; Eric Leas; Martha M White; David R Strong; Madison L Noble; Dennis R Trinidad Journal: Am J Epidemiol Date: 2018-11-01 Impact factor: 4.897
Authors: Erin L Sutfin; Beth A Reboussin; Beata Debinski; Kimberly G Wagoner; John Spangler; Mark Wolfson Journal: Am J Public Health Date: 2015-06-11 Impact factor: 9.308
Authors: Godfred O Antwi; David K Lohrmann; Wasantha Jayawardene; Angela Chow; Cecilia S Obeng; Aaron M Sayegh Journal: J Cancer Surviv Date: 2019-04-06 Impact factor: 4.442
Authors: Su Hyun Park; Dustin T Duncan; Omar El Shahawy; Lily Lee; Jenni A Shearston; Kosuke Tamura; Scott E Sherman; Michael Weitzman Journal: Am J Prev Med Date: 2017-08-29 Impact factor: 5.043
Authors: Eleni M Rettig; Carole Fakhry; Russell K Hales; Flora Kisuule; Harry Quon; Ana P Kiess; Linda X Yin; Yuehan Zhang; Amanda L Blackford; M Bradley Drummond; Christine G Gourin; Wayne M Koch; David W Eisele; Gypsyamber D'Souza Journal: Head Neck Date: 2018-03-15 Impact factor: 3.147
Authors: Jessica L Burris; Jamie L Studts; Antonio P DeRosa; Jamie S Ostroff Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-08-17 Impact factor: 4.254